Singapore - English - HSA (Health Sciences Authority)

nature's green - granules

European Union - English - EMA (European Medicines Agency)

n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of postmenopausal osteoporosis in patients at risk of vitamin-d insufficiency.adrovance reduces the risk of vertebral and hip fractures.

European Union - English - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of postmenopausal osteoporosis in patients at risk of vitamin-d insufficiency.fosavance reduces the risk of vertebral and hip fractures.

European Union - English - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of postmenopausal osteoporosis in patients at risk of vitamin-d insufficiency.vantavo reduces the risk of vertebral and hip fractures.treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-d supplementation and are at risk of vitamin-d insufficiency.vantavo reduces the risk of vertebral and hip fractures.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Canada - English - Health Canada

roter pharmaceutische fabriek - bismuth subnitrate; magnesium carbonate; sodium bicarbonate; alder buckthorn - tablet - 350mg; 400mg; 200mg; 25mg - bismuth subnitrate 350mg; magnesium carbonate 400mg; sodium bicarbonate 200mg; alder buckthorn 25mg - antacids and adsorbents

Canada - English - Health Canada

d.c. labs limited - sodium bicarbonate - tablet - 300mg - sodium bicarbonate 300mg - antacids and adsorbents